Drug Trial Radar · NCT00042458
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
Last checked: Nov 20, 2026Latest source record: Sep 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
296
Actual
Start
Apr 2002
Primary completion
Mar 2003
Study completion Mar 2003
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 1, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, triple-blind, placebo-controlled, multicenter study to investigate the safety of pramlintide treatment using pramlintide dose-titration coupled with insulin adjustments in subjects with type 1 diabetes who are actively trying to improve their glycemic control.
Conditions
- Diabetes Mellitus, Type 1
Interventions
Pramlintide acetateDrug
Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
PlaceboDrug
The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
Primary outcomes
What the sponsor says the trial is designed to measure.
- - To investigate the safety of pramlintide treatment employing dose titration upon initiation of pramlintide followed by insulin dose optimization in subjects with type 1 diabetes.Time frame: 29 Weeks
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Ana Ventures LLC
Mesa, Arizona
Phoenix Endocrinology Clinic, Ltd.
Phoenix, Arizona
East Bay Clinical Trial Center
Concord, California
Valley Research
Fresno, California
UCSD Diabetes Research Center
San Diego, California
Diabetes Research Institute
San Mateo, California
Sansum Medical Research Institute
Santa Barbara, California
Diablo Clinical Research
Walnut Creek, California
Barbara Davis Center for Childhood Diabetes
Denver, Colorado
MedStar Clinical Research Center
Washington D.C., District of Columbia
Medical Research Unlimited
Aventura, Florida
Medical Research Unlimited
Aventura, Florida
Internal Medicine Associates
Fort Myers, Florida
Suncoast Clinical Research
New Port Richey, Florida
Children's Clinic
Tallahassee, Florida
Atlanta Diabetes Associates
Atlanta, Georgia
St. James Diabetes Center
Chicago Heights, Illinois
St. James Diabetes Center
Chicago Heights, Illinois
Indiana University Outpatient Clinical Research
Indianapolis, Indiana
University of Maryland Joslin Diabetes Center
Baltimore, Maryland
Henry Ford Health System
Detroit, Michigan
Grand Rapids Associated Interns
Grand Rapids, Michigan
Radiant Research
St Louis, Missouri
Mercury Street Medical
Butte, Montana
UNC Diabetes Care Center
Durham, North Carolina
Ohio State Univ.-Division of Endocrinology, Diabetes
Columbus, Ohio
Radiant Research
Portland, Oregon
Physicians for Clinical Research
Camp Hill, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
North Texas Clinical Research
Irving, Texas
Private Practice
Lufkin, Texas
Private Practice
Lufkin, Texas
Rainier Clinical Research Center
Renton, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.